View Financial HealthGB Sciences 배당 및 자사주 매입배당 기준 점검 0/6GB Sciences 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률7.3%자사주 매입 수익률총 주주 수익률7.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Jul 12Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of LethbridgeGb Sciences, Inc. has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model. In addition to the dosage range findings, this study demonstrated that Gb Sciences' Parkinson's disease formulations were well tolerated, and there were no adverse effects. As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson's disease (PD) treatments is expected to grow to $12.8 billion by 2028. The dose response study in rodents performed at the University of Lethbridge helps to establish the correct dosing of Gb Sciences' cannabinoid-containing Parkinson's formulations for a first-in-human trial. Dr. Robert Sutherland, Ph.D., FRSC, Professor and Chair of the Department of Neuroscience at the University of Lethbridge, Board of Governors Research Chair in Neuroscience, and Director of the Canadian Centre for Behavioral Neuroscience, used deep learning models to analyze the rich data sets from their "Home Cage Small World" behavioral assessments of rodents with video cameras and Artificial Intelligence, using a system developed by Neurocage Systems Ltd. Future studies confirming the mechanism of action of these cannabinoid-based Parkinson's formulations are planned with Dr. Sutherland's research group at the University of Lethbridge using their behavioral measurement methods for rodents.공지 • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Jan 20GB Sciences, Inc., Annual General Meeting, Mar 09, 2023GB Sciences, Inc., Annual General Meeting, Mar 09, 2023, at 10:00 Pacific Standard Time. Agenda: To consider and elect three directors to serve on Board of Directors and until each of their successors has been duly elected and qualified, unless such individuals shall sooner die, resign or be removed; to approve an amendment to articles of incorporation to increase the number of shares of stock Board of Directors is authorized to issue from 600,000,000 shares to 950,000,000 shares; to ratify the appointment of Assurance Dimensions as independent registered public accounting firm for the fiscal year ended March 31, 2023; and to transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.공지 • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2022, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Mar 30Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research ArticleGb Sciences, Inc. announced that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes versus the effect of free terpenes in a cell model with TRPV1 receptors, which are known pain receptors. The study found that the encapsulated terpene nanoparticles produced significantly higher calcium responses alone or in combinations versus the free terpenes alone or in combinations. The elevated calcium responses through the TRPV1 channels indicate greater activation of these pain receptors, which can have an analgesic effect via desensitization of these important pain receptors.공지 • Mar 03GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary CystitisGb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups. Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease.공지 • Jan 13An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million.An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million on December 31, 2021. The sale, valued at $8 million, will allow Gb Sciences to reduce outstanding debt and bolster its cash position. The proceeds from this sale include $1.2 million in cash, $3.8 million in immediate debt and liabilities reduction, and a $3 million interest-bearing note payable to Gb Sciences by the buyer over a three-year term. An unknown buyer completed the acquisition of Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) on December 31, 2021.공지 • Sep 15GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related HyperinflammationGb Sciences, Inc. received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August 18, 2021. The best-performing cannabinoid-containing complex mixtures will be further developed in preparation for clinical studies to evaluate their anti-inflammatory potential in the treatment of severely ill COVID-19 patients contending with Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions, such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS). CRS, MAS, and ARDS are the leading causes of death in COVID-19 patients.공지 • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2021, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Nov 26GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of DirectorsGB Sciences, Inc. announced that effective November 23, 2020, Mr. Leslie Bocskor resigned his position as a member of the board of directors of the Company to pursue other business interests.공지 • Sep 19Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX).Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. GB Sciences did not receive any consideration in the transaction but was relieved of any obligation to fund the losses of GB Sciences Puerto Rico going forward. As the result of the transaction, GB Sciences deconsolidated the assets, liabilities and noncontrolling interests of GB Sciences Puerto Rico since its ownership interest was reduced to a non-controlling level. Cesar Cordero-Kruger completed the acquisition of an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017.공지 • Aug 18GB Sciences, Inc. announced delayed 10-Q filingOn 08/17/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Aug 14GB Sciences, Inc. announced delayed annual 10-K filingOn 08/13/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GBLX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GBLX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장GB Sciences 배당 수익률 vs 시장GBLX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GBLX)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.2%분석가 예측 (GBLX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GBLX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GBLX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GBLX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GBLX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 06:16종가2026/05/11 00:00수익2024/12/31연간 수익2024/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GB Sciences, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공지 • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Jul 12Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of LethbridgeGb Sciences, Inc. has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model. In addition to the dosage range findings, this study demonstrated that Gb Sciences' Parkinson's disease formulations were well tolerated, and there were no adverse effects. As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson's disease (PD) treatments is expected to grow to $12.8 billion by 2028. The dose response study in rodents performed at the University of Lethbridge helps to establish the correct dosing of Gb Sciences' cannabinoid-containing Parkinson's formulations for a first-in-human trial. Dr. Robert Sutherland, Ph.D., FRSC, Professor and Chair of the Department of Neuroscience at the University of Lethbridge, Board of Governors Research Chair in Neuroscience, and Director of the Canadian Centre for Behavioral Neuroscience, used deep learning models to analyze the rich data sets from their "Home Cage Small World" behavioral assessments of rodents with video cameras and Artificial Intelligence, using a system developed by Neurocage Systems Ltd. Future studies confirming the mechanism of action of these cannabinoid-based Parkinson's formulations are planned with Dr. Sutherland's research group at the University of Lethbridge using their behavioral measurement methods for rodents.
공지 • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Jan 20GB Sciences, Inc., Annual General Meeting, Mar 09, 2023GB Sciences, Inc., Annual General Meeting, Mar 09, 2023, at 10:00 Pacific Standard Time. Agenda: To consider and elect three directors to serve on Board of Directors and until each of their successors has been duly elected and qualified, unless such individuals shall sooner die, resign or be removed; to approve an amendment to articles of incorporation to increase the number of shares of stock Board of Directors is authorized to issue from 600,000,000 shares to 950,000,000 shares; to ratify the appointment of Assurance Dimensions as independent registered public accounting firm for the fiscal year ended March 31, 2023; and to transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.
공지 • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2022, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Mar 30Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research ArticleGb Sciences, Inc. announced that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes versus the effect of free terpenes in a cell model with TRPV1 receptors, which are known pain receptors. The study found that the encapsulated terpene nanoparticles produced significantly higher calcium responses alone or in combinations versus the free terpenes alone or in combinations. The elevated calcium responses through the TRPV1 channels indicate greater activation of these pain receptors, which can have an analgesic effect via desensitization of these important pain receptors.
공지 • Mar 03GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary CystitisGb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups. Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease.
공지 • Jan 13An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million.An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million on December 31, 2021. The sale, valued at $8 million, will allow Gb Sciences to reduce outstanding debt and bolster its cash position. The proceeds from this sale include $1.2 million in cash, $3.8 million in immediate debt and liabilities reduction, and a $3 million interest-bearing note payable to Gb Sciences by the buyer over a three-year term. An unknown buyer completed the acquisition of Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) on December 31, 2021.
공지 • Sep 15GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related HyperinflammationGb Sciences, Inc. received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August 18, 2021. The best-performing cannabinoid-containing complex mixtures will be further developed in preparation for clinical studies to evaluate their anti-inflammatory potential in the treatment of severely ill COVID-19 patients contending with Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions, such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS). CRS, MAS, and ARDS are the leading causes of death in COVID-19 patients.
공지 • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2021, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Nov 26GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of DirectorsGB Sciences, Inc. announced that effective November 23, 2020, Mr. Leslie Bocskor resigned his position as a member of the board of directors of the Company to pursue other business interests.
공지 • Sep 19Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX).Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. GB Sciences did not receive any consideration in the transaction but was relieved of any obligation to fund the losses of GB Sciences Puerto Rico going forward. As the result of the transaction, GB Sciences deconsolidated the assets, liabilities and noncontrolling interests of GB Sciences Puerto Rico since its ownership interest was reduced to a non-controlling level. Cesar Cordero-Kruger completed the acquisition of an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017.
공지 • Aug 18GB Sciences, Inc. announced delayed 10-Q filingOn 08/17/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Aug 14GB Sciences, Inc. announced delayed annual 10-K filingOn 08/13/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.